Comorbilidades asociadas a mortalidad o enfermedad severa en pacientes hospitalizados con COVID-19 / Comorbidities associated with mortality or severe disease in hospitalized patients with COVID-19

Objetivo: Conocer las comorbilidades de los pacientes hospitalizados con COVID-19 e identificar cuales se asocian a mayor severidad y/o mortalidad intrahospitalaria. Métodos: Estudio de cohortes retrospectivo en el que se incluyeron todos los pacientes ingresados con COVID-19 desde 1 de marzo del 2020 hasta el 31 mayo de 2020. Se realizó un análisis descriptivo de las comorbilidades y se vio cuales se asocian a una mayor mortalidad intrahospitalaria y/o severidad de la enfermedad mediante un modelo de regresión logística binaria. Resultados: Un total de 336 pacientes fueron incluidos en el estudio de los cuales 52 (15,5%) fallecieron durante el ingreso. Un 58% eran varones, la edad media fue 66 años y el índice Charlson fue de 1. En el análisis multivariante se identificaron como comorbilidades asociadas a mortalidad la edad > 65 años (OR 2,65; p 0,021), el sexo masculino (OR 3,26; p 0,004), la enfermedad cardiovascular ateroesclerótica (OR 2,11; p<0,040) y no ateroesclerótica (OR 6,40; p<0,001) y la neoplasia (OR 5,09; p<0,001). Se asociaron a mayor severidad de la COVID-19 la edad> 65 años (OR 1,87; p 0,033), el sexo masculino (OR 2,86; p <0,001), la obesidad (OR 1,82; p 0,034) y SAOS (OR 5,26; p 0,006). Conclusiones: La enfermedad cardiovascular previa y la neoplasia se asocian a mortalidad intrahospitalaria mientras que la obesidad y el SAOS se asocian a severidad de la enfermedad en pacientes hospitalizados con COVID-19. La edad >65 años y el sexo masculino se asocian a una mayor severidad y mortalidad intrahospitalaria. (AU)

Objective: To evaluate the comorbidities in hospitalized patients with COVID-19 and identify which ones are associated with severe COVID-19 disease and/or in-hospital mortality. Methods: A retrospective cohort study was performed. All patients admitted with confirmed COVID-19 from March 1, 2020 to May 31, 2020 were included. A descriptive analysis of comorbidities was made. We evaluated what comorbidities are associated with in-hospital mortality and/or severe COVID-19 disease using a binary logistic regression model. Results: A total of 336 patients were included in the study: 52 (15,5%) died during hospitalization. Mean age was 66 + 14 years, 58% were men and the Charlson Comorbidity Index was 1. In multivariate analysis, age >65 years (HR 2,65; p 0,021), male sex (HR 3,26; p 0,004), atherosclerotic cardiovascular disease (HR 2,11; p 0,040), non-atherosclerotic cardiovascular disease (HR 6,40; p<0,001) and malignancy (HR 5,09; p< 0,001), were identified as comorbidities associated with in hospital-mortality. Age >65 years (HR 1,87; p 0,033), male sex (HR 2,86; p<0,001), obesity (HR 1,82; p 0,034) and obstructive sleep apnea (HR 5,26; p 0,006) were associated with severe COVID-19 disease. Conclusions: Previous cardiovascular disease and malignancy are risk factors of in-hospital mortality while obesity and obstructive sleep apnea are associated with severe COVID-19 disease in hospitalized patients. Age >65 years and male sex are associated with both. (AU)

Factores clínicos asociados a enfermedad pulmonar por Aspergillus spp. en pacientes con enfermedad pulmonar obstructiva crónica / Clinical factors associated with pulmonary aspergillosis in patients with chronic obstructive pulmonary disease

OBJETIVO: Conocer las características clínicas y epidemiológicas de los pacientes con enfermedad pulmonar obstructiva crónica (EPOC) y aislamiento de especies de Aspergillus en muestra respiratoria e identificar factores que nos ayuden a diferenciar entre colonización e infección. MÉTODOS: Estudio de cohortes retrospectivo en el que se incluyeron todos los pacientes con EPOC y aislamiento de Aspergillus spp. en muestra respiratoria durante un periodo de 12 años. Se asignaron los pacientes a 2 categorías: colonización y aspergilosis pulmonar (AP), que incluye las diferentes formas de presentación clínica. Se aplicó un modelo de regresión logística binaria para identificar los factores predictores de desarrollo de AP. RESULTADOS: Un total de 123 pacientes fueron incluidos en el estudio: 48 (39%) colonizados y 75 (61%) con AP: 68 con AP invasiva probable y 7 con AP crónica. No hubo correlación entre el riesgo de AP y los estadios espirométricos de la clasificación GOLD. Se identificaron como factores predictores independientes de AP en pacientes con EPOC la oxigenoterapia domiciliaria (OR: 4,39; IC 95%: 1,60-12,01; p = 0,004), las bronquiectasias (OR: 3,61; IC 95%: 1,40-9,30; p = 0,008), la hospitalización en los 3 meses previos al ingreso (OR: 3,12; IC 95%: 1,24-7,87; p = 0,016) y la terapia antifúngica frente a Candida spp. en el mes previo (OR: 3,18; IC 95%: 1,16-8,73; p = 0,024). CONCLUSIONES: La oxigenoterapia continua domiciliaria, las bronquiectasias, la hospitalización en los 3 meses previos al ingreso y la utilización de terapia antifúngica frente a Candida spp. en el mes previo se asocian a mayor riesgo de AP en pacientes con EPOC

OBJECTIVE: To explore the clinical and epidemiological characteristics of chronic obstructive pulmonary disease (COPD) patients with Aspergillus spp. isolation from respiratory samples, and to identify which factors may help us to distinguish between colonisation and infection. METHODS: A retrospective cohort study was performed. All patients with COPD and respiratory isolation of Aspergillus spp. over a 12-year period were included. Patients were assigned to 2 categories: colonisation and pulmonary aspergillosis (PA), which includes the different clinical forms of aspergillosis. A binary logistic regression model was performed to identify the predictive factors of PA. RESULTS: A total of 123 patients were included in the study: 48 (39.0%) with colonisation and 75 (61.0%) with PA: 68 with probable invasive pulmonary aspergillosis and 7 with chronic pulmonary aspergillosis. Spirometric stages of the GOLD classification were not correlated with a higher risk of PA. Four independent predictive factors of PA in COPD patients were identified: home oxygen therapy (OR: 4.39; 95% CI: 1.60-12.01; P = .004), bronchiectasis (OR: 3.61; 95% CI: 1.40-9.30; P = .008), hospital admission in the previous three months (OR: 3.12; 95% CI: 1.24-7.87; P = .016) and antifungal therapy against Candida spp. in the previous month (OR: 3.18; 95% CI: 1.16-8.73; P = .024). CONCLUSIONS: Continuous home oxygen therapy, bronchiectasis, hospital admission in the previous three months and administration of antifungal medication against Candida spp. in the previous month were associated with a higher risk of pulmonary aspergillosis in patients with COPD

Clinical factors associated with pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. / Factores clínicos asociados a enfermedad pulmonar por Aspergillus spp. en pacientes con enfermedad pulmonar obstructiva crónica.

OBJECTIVE: To explore the clinical and epidemiological characteristics of chronic obstructive pulmonary disease (COPD) patients with Aspergillus spp. isolation from respiratory samples, and to identify which factors may help us to distinguish between colonisation and infection. METHODS: A retrospective cohort study was performed. All patients with COPD and respiratory isolation of Aspergillus spp. over a 12-year period were included. Patients were assigned to 2 categories: colonisation and pulmonary aspergillosis (PA), which includes the different clinical forms of aspergillosis. A binary logistic regression model was performed to identify the predictive factors of PA. RESULTS: A total of 123 patients were included in the study: 48 (39.0%) with colonisation and 75 (61.0%) with PA: 68 with probable invasive pulmonary aspergillosis and 7 with chronic pulmonary aspergillosis. Spirometric stages of the GOLD classification were not correlated with a higher risk of PA. Four independent predictive factors of PA in COPD patients were identified: home oxygen therapy (OR: 4.39; 95% CI: 1.60-12.01; P=.004), bronchiectasis (OR: 3.61; 95% CI: 1.40-9.30; P=.008), hospital admission in the previous three months (OR: 3.12; 95% CI: 1.24-7.87; P=.016) and antifungal therapy against Candida spp. in the previous month (OR: 3.18; 95% CI: 1.16-8.73; P=.024). CONCLUSIONS: Continuous home oxygen therapy, bronchiectasis, hospital admission in the previous three months and administration of antifungal medication against Candida spp. in the previous month were associated with a higher risk of pulmonary aspergillosis in patients with COPD.